8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Feb 19, 2026·SEC
Traws Pharma, Inc.(TRAW)Earnings, Financials & Key Ratios
TRAW•NASDAQ
$1.70
$3M mkt cap·Price updated May 6, 2026
AboutTraws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Show more
- Revenue$226K
- EBITDA-$49M-143.3%
- Net Income-$55M-188.5%
- EPS (Diluted)-35.21-56.0%
- Gross Margin94.69%-5.3%
- EBITDA Margin-21830.09%-143.3%
- Operating Margin-21835.4%-143.1%
- Net Margin-24192.04%-188.5%
TRAW Key Insights
Traws Pharma, Inc. (TRAW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 36.5% over 5 years
- ✗Shares diluted 84.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TRAW Price & Volume
Traws Pharma, Inc. (TRAW) stock price & volume — 10-year historical chart
Loading chart...
TRAW Growth Metrics
Traws Pharma, Inc. (TRAW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-11.87%
5 Years-36.47%
3 Years0%
TTM554.65%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM36.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM42.82%
Return on Capital
10 Years-286.31%
5 Years-151.82%
3 Years-168.77%
Last Year-367.01%
TRAW Peer Comparison
Traws Pharma, Inc. (TRAW) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VRTX | 108.78B | 427.65 | 27.91 | 9.57% | 35.4% | 23.93% | 0.21 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 AVIR | 441.42M | 5.65 | -2.91 | -38.43% | 0.00 | |||
 COCP | 18.39M | 1.41 | -0.82 | -126.11% | 0.19 | |||
 ABUS | 850.99M | 4.42 | -26 | 128.21% | -237.88% | -42.39% | 0.01 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare TRAW vs Peers
Traws Pharma, Inc. (TRAW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TRAW Income Statement
Traws Pharma, Inc. (TRAW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.55M | 787K | 1.23M | 2.18M | 231K | 226K | 226K | 226K | 226K | 2.96M |
| Revenue Growth % | -51.59% | -85.81% | 56.04% | 77.77% | -89.42% | -2.16% | 0% | 0% | 0% | 554.65% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 6K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 5.31% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 2.18M▲ 0% | 231K▼ 89.4% | 226K▼ 2.2% | 226K▲ 0.0% | 226K▲ 0.0% | 214K▼ 5.3% | 2.95M▲ 0% |
| Gross Margin % | - | - | - | 100% | 100% | 100% | 100% | 100% | 94.69% | 99.8% |
| Gross Profit Growth % | - | - | - | - | -89.42% | -2.16% | 0% | 0% | -5.31% | - |
| Operating Expenses | 29.15M | 26.44M | 24.45M | 23.88M | 25.22M | 16.72M | 19.85M | 20.52M | 49.56M | 27.5M |
| OpEx % of Revenue | 525.66% | 3359.09% | 1991.45% | 1094% | 10919.48% | 7399.12% | 8784.51% | 9081.42% | 21930.09% | - |
| Selling, General & Admin | 9.08M | 7.41M | 7.59M | 8.35M | 8.33M | 9.43M | 8.45M | 9.09M | 12.29M | 14.98M |
| SG&A % of Revenue | 163.76% | 940.91% | 617.75% | 382.27% | 3604.33% | 4170.35% | 3737.61% | 4023.89% | 5437.61% | - |
| Research & Development | 20.07M | 19.03M | 16.87M | 15.54M | 16.9M | 7.3M | 11.41M | 11.43M | 130.31M | 16.5M |
| R&D % of Revenue | 361.9% | 2418.17% | 1373.7% | 711.73% | 7315.15% | 3228.76% | 5046.9% | 5057.52% | 57659.73% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -93.04M | -1000K |
| Operating Income | -23.7M▲ 0% | -25.74M▼ 8.6% | -23.28M▲ 9.5% | -21.7M▲ 6.8% | -24.99M▼ 15.2% | -16.5M▲ 34.0% | -19.63M▼ 19.0% | -20.3M▼ 3.4% | -49.35M▼ 143.1% | -24.55M▲ 0% |
| Operating Margin % | -427.39% | -3270.27% | -1895.93% | -994% | -10819.48% | -7299.12% | -8684.51% | -8981.42% | -21835.4% | -829.6% |
| Operating Income Growth % | 1.12% | -8.58% | 9.54% | 6.8% | -15.18% | 34% | -18.98% | -3.42% | -143.12% | - |
| EBITDA | -23.61M | -25.65M | -23.23M | -21.68M | -24.98M | -16.48M | -19.61M | -20.28M | -49.34M | -24.53M |
| EBITDA Margin % | -425.66% | -3259.09% | -1891.45% | -993.36% | -10813.85% | -7292.92% | -8678.32% | -8974.34% | -21830.09% | -829.03% |
| EBITDA Growth % | 0.9% | -8.65% | 9.44% | 6.64% | -15.19% | 34.02% | -19% | -3.41% | -143.25% | 35.61% |
| D&A (Non-Cash Add-back) | 96K | 88K | 55K | 14K | 13K | 14K | 14K | 16K | 12K | 17K |
| EBIT | -19.65M | -24.08M | -20.53M | -21.7M | -24.99M | -16.5M | -19.63M | -20.3M | -166.52M | -25.46M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.05M | 1.66M | 2.75M | 206K | -160K | 333K | 663K | 1.35M | -117.17M | 1.25M |
| Pretax Income | -19.65M▲ 0% | -24.08M▼ 22.5% | -20.53M▲ 14.7% | -21.49M▼ 4.7% | -25.15M▼ 17.0% | -16.16M▲ 35.7% | -18.96M▼ 17.3% | -18.95M▲ 0.1% | -166.52M▼ 778.8% | -23.3M▲ 0% |
| Pretax Margin % | -354.36% | -3059.59% | -1672.15% | -984.56% | -10888.74% | -7151.77% | -8391.15% | -8384.07% | -73682.74% | -787.29% |
| Income Tax | 14K | 13K | -124K | 10K | 4K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.07% | -0.05% | 0.6% | -0.05% | -0.02% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -19.67M▲ 0% | -24.09M▼ 22.5% | -20.57M▲ 14.6% | -21.5M▼ 4.5% | -25.16M▼ 17.0% | -16.16M▲ 35.8% | -18.96M▼ 17.3% | -18.95M▲ 0.1% | -54.67M▼ 188.5% | -23.01M▲ 0% |
| Net Margin % | -354.62% | -3061.25% | -1675.33% | -985.02% | -10890.48% | -7151.77% | -8391.15% | -8384.07% | -24192.04% | -777.49% |
| Net Income Growth % | 17.98% | -22.5% | 14.61% | -4.52% | -16.99% | 35.75% | -17.33% | 0.08% | -188.55% | 36.46% |
| Net Income (Continuing) | -19.67M | -24.09M | -20.41M | -21.5M | -25.16M | -16.16M | -18.96M | -18.95M | -166.52M | -23.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 830K | 830K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -24975.00▲ 0% | -15056.00▲ 39.7% | -1870.69▲ 87.6% | -560.58▲ 70.0% | -54.21▲ 90.3% | -24.01▲ 55.7% | -22.68▲ 5.5% | -22.57▲ 0.5% | -35.21▼ 56.0% | -3.95▲ 0% |
| EPS Growth % | 57.71% | 39.72% | 87.58% | 70.03% | 90.33% | 55.71% | 5.54% | 0.47% | -56.01% | 42.82% |
| EPS (Basic) | -24975.00 | -15056.00 | -1870.69 | -560.58 | -54.21 | -24.01 | -22.68 | -22.57 | -35.21 | - |
| Diluted Shares Outstanding | 787 | 1.6K | 11K | 38.36K | 464.1K | 673.29K | 836.33K | 839.55K | 1.55M | 5.82M |
| Basic Shares Outstanding | 787 | 1.6K | 11K | 38.36K | 464.1K | 673.29K | 836.33K | 839.55K | 1.55M | 5.82M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TRAW Balance Sheet
Traws Pharma, Inc. (TRAW) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 23.07M | 4.9M | 17.77M | 23.47M | 19.78M | 55.43M | 39.35M | 22.66M | 24.95M | 15.37M |
| Cash & Short-Term Investments | 21.45M | 4.02M | 16.97M | 22.73M | 19.02M | 55.07M | 38.76M | 20.82M | 21.34M | 13.08M |
| Cash Only | 21.45M | 4.02M | 16.97M | 22.73M | 19.02M | 55.07M | 38.76M | 20.82M | 21.34M | 13.08M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 31K | 59K | 35K | 98K | 37K | 28K | 29K | 18K | 1.76M | 1.32M |
| Days Sales Outstanding | 2.04 | 27.36 | 10.4 | 16.39 | 58.46 | 45.22 | 46.84 | 29.07 | 2.85K | 96.34 |
| Inventory | 0 | 0 | 0 | 0 | 542K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 21.6K |
| Other Current Assets | 73K | 77K | 68K | 140K | -362K | 35K | 40K | 401K | 178K | 124K |
| Total Non-Current Assets | 164K | 76K | 158K | 200K | 202K | 48K | 25K | 23K | 11K | 252K |
| Property, Plant & Equipment | 152K | 64K | 9K | 50K | 52K | 38K | 24K | 22K | 10K | 8K |
| Fixed Asset Turnover | 36.49x | 12.30x | 136.44x | 43.66x | 4.44x | 5.95x | 9.42x | 10.27x | 22.60x | 219.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 12K | 12K | 149K | 150K | 150K | 10K | 1K | 1K | 1K | 247K |
| Total Assets | 23.23M▲ 0% | 4.98M▼ 78.6% | 17.92M▲ 260.0% | 23.67M▲ 32.1% | 19.99M▼ 15.6% | 55.48M▲ 177.6% | 39.37M▼ 29.0% | 22.68M▼ 42.4% | 24.96M▲ 10.0% | 15.62M▲ 0% |
| Asset Turnover | 0.24x | 0.16x | 0.07x | 0.09x | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x | 0.14x |
| Asset Growth % | -0.9% | -78.57% | 259.97% | 32.09% | -15.58% | 177.58% | -29.03% | -42.39% | 10.05% | -87.41% |
| Total Current Liabilities | 10.16M | 9.98M | 8.44M | 8.29M | 10.02M | 6.12M | 8.05M | 9.22M | 11.53M | 7.35M |
| Accounts Payable | 5.32M | 6.19M | 4.04M | 4.27M | 4.83M | 2.76M | 3.86M | 5.62M | 8.19M | 4.76M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 248.99K | 376.22K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 455K | 455K | 226K | 226K | 226K | 226K | 226K | 226K | 226K | 679K |
| Other Current Liabilities | 2.81M | 1.26M | 2.52M | 2.26M | 2.72M | 1.92M | 1.19M | 2.37M | 265K | 502K |
| Current Ratio | 2.27x | 0.49x | 2.11x | 2.83x | 1.97x | 9.06x | 4.89x | 2.46x | 2.16x | 2.16x |
| Quick Ratio | 2.27x | 0.49x | 2.11x | 2.83x | 1.92x | 9.06x | 4.89x | 2.46x | 2.16x | 2.16x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -354.53K |
| Total Non-Current Liabilities | 7.95M | 5.86M | 4.1M | 3.81M | 3.79M | 3.24M | 3.02M | 2.79M | 45.06M | 8K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.4M | 1.77M | 176K | 113K | 321K | 0 | 0 | 0 | 42.49M | 154.12M |
| Total Liabilities | 18.11M | 15.84M | 12.54M | 12.1M | 13.81M | 9.36M | 11.06M | 12.01M | 56.59M | 7.36M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -21.45M | -4.02M | -16.97M | -22.73M | -19.02M | -55.07M | -38.76M | -20.82M | -21.34M | -13.08M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.53x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 5.13M▲ 0% | -10.86M▼ 311.8% | 5.39M▲ 149.6% | 11.57M▲ 114.9% | 6.17M▼ 46.6% | 46.12M▲ 646.9% | 28.31M▼ 38.6% | 10.67M▼ 62.3% | -31.63M▼ 396.4% | 8.26M▲ 0% |
| Equity Growth % | -52.7% | -311.84% | 149.6% | 114.85% | -46.65% | 646.88% | -38.62% | -62.3% | -396.38% | -1009.22% |
| Book Value per Share | 6514.96 | -6788.13 | 489.86 | 301.74 | 13.31 | 68.50 | 33.85 | 12.71 | -20.37 | 1.42 |
| Total Shareholders' Equity | 4.3M | -11.69M | 5.39M | 11.57M | 6.17M | 46.12M | 28.31M | 10.67M | -31.63M | 8.26M |
| Common Stock | 68K | 8K | 57K | 1.11M | 124K | 209K | 209K | 210K | 36K | 71K |
| Retained Earnings | -338.22M | -362.32M | -381.9M | -403.4M | -428.56M | -444.72M | -463.68M | -482.63M | -649.15M | -628.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -31K | 3K | -12K | -18K | 14K | -14K | -33K | -23K | -42K | 9K |
| Minority Interest | 830K | 830K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TRAW Cash Flow Statement
Traws Pharma, Inc. (TRAW) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.81M | -23.82M | -22.7M | -20.83M | -23.07M | -19.49M | -16.29M | -17.93M | -29.79M | -29.79M |
| Operating CF Margin % | -285.12% | -3026.68% | -1848.21% | -954.24% | -9989.18% | -8622.57% | -7209.73% | -7934.51% | -13182.3% | - |
| Operating CF Growth % | 49.38% | -50.64% | 4.72% | 8.22% | -10.77% | 15.55% | 16.39% | -10.05% | -66.14% | -88.61% |
| Net Income | -19.67M | -24.09M | -20.57M | -21.5M | -25.16M | -16.16M | -18.96M | -18.95M | -166.52M | -23.01M |
| Depreciation & Amortization | 96K | 88K | 55K | 14K | 13K | 14K | 14K | 16K | 12K | 23K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 369K | 576K | 1.17M | 1.3M | 1.39M | 1.93M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -869K |
| Other Non-Cash Items | -3.24M | -577K | 429K | 985K | 208K | -321K | 0 | 0 | 141.9M | 148.82M |
| Working Capital Changes | 3.82M | 102K | -1.07M | -327K | 1.49M | -3.59M | 1.48M | -301K | -6.57M | -17.3M |
| Change in Receivables | 1.47M | -28K | 24K | -63K | 61K | 9K | -1K | 11K | -1.75M | -1.09M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.9M | 863K | -1.45M | 232K | 562K | -2.08M | 1.1M | 1.76M | 646K | -4.81M |
| Cash from Investing | 0 | 0 | 0 | -55K | -15K | 0 | 0 | -14K | -3.65M | -3.66M |
| Capital Expenditures | 0 | 0 | 0 | -55K | -15K | 0 | 0 | -14K | 0 | -14K |
| CapEx % of Revenue | - | - | - | 2.52% | 6.49% | - | - | 6.19% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.65M | -3.65M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 17.42M | 6.36M | 35.66M | 26.65M | 19.36M | 55.56M | 0 | 0 | 33.98M | 37.07M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3K | 0 | 589K | 4.89M | 10.29M | 519K | 0 | 0 | 0 | -3.42M |
| Net Change in Cash | 1.61M▲ 0% | -17.43M▼ 1182.4% | 12.95M▲ 174.3% | 5.76M▼ 55.5% | -3.7M▼ 164.3% | 36.05M▲ 1073.9% | -16.31M▼ 145.3% | -17.94M▼ 9.9% | 517K▲ 102.9% | 9.14M▲ 0% |
| Free Cash Flow | -15.81M▲ 0% | -23.82M▼ 50.6% | -22.7M▲ 4.7% | -20.89M▲ 8.0% | -23.09M▼ 10.6% | -19.49M▲ 15.6% | -16.29M▲ 16.4% | -17.95M▼ 10.1% | -29.79M▼ 66.0% | -50.66M▲ 0% |
| FCF Margin % | -285.12% | -3026.68% | -1848.21% | -956.76% | -9995.67% | -8622.57% | -7209.73% | -7940.71% | -13182.3% | -1712.17% |
| FCF Growth % | 49.38% | -50.64% | 4.72% | 7.98% | -10.55% | 15.6% | 16.39% | -10.14% | -66.01% | -49.63% |
| FCF per Share | -20093.83 | -14887.50 | -2063.84 | -544.50 | -49.75 | -28.94 | -19.48 | -21.38 | -19.19 | -19.19 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.99x | 1.10x | 0.97x | 0.92x | 1.21x | 0.86x | 0.95x | 0.54x | 2.20x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TRAW Key Ratios
Traws Pharma, Inc. (TRAW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -246.35% | - | -381.9% | -253.56% | -283.48% | -61.81% | -50.96% | -97.22% | - | -278.46% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 38.69% |
| Gross Margin | - | - | - | 100% | 100% | 100% | 100% | 100% | 94.69% | 99.8% |
| Net Margin | -354.62% | -3061.25% | -1675.33% | -985.02% | -10890.48% | -7151.77% | -8391.15% | -8384.07% | -24192.04% | -777.49% |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| FCF Conversion | 0.80x | 0.99x | 1.10x | 0.97x | 0.92x | 1.21x | 0.86x | 0.95x | 0.54x | 2.20x |
| Revenue Growth | -51.59% | -85.81% | 56.04% | 77.77% | -89.42% | -2.16% | 0% | 0% | 0% | 554.65% |
TRAW SEC Filings & Documents
Traws Pharma, Inc. (TRAW) SEC filings — annual & quarterly reports (10-K, 10-Q)
TRAW Frequently Asked Questions
Traws Pharma, Inc. (TRAW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Traws Pharma, Inc. (TRAW) reported $3.0M in revenue for fiscal year 2024. This represents a 99% increase from $1.5M in 2011.
Traws Pharma, Inc. (TRAW) grew revenue by 0.0% over the past year. Growth has been modest.
Traws Pharma, Inc. (TRAW) reported a net loss of $23.0M for fiscal year 2024.
Dividend & Returns
Traws Pharma, Inc. (TRAW) had negative free cash flow of $50.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More TRAW
Traws Pharma, Inc. (TRAW) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates